Astrazeneca ADR Stock
Your prediction
Astrazeneca ADR Stock
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Astrazeneca ADR stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Astrazeneca ADR in the next few years
Pros
?
C******** o* t** e**********
?
S********** s********
?
M***** P*******
Cons
?
G***** c******* t* c**********
?
B****
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Astrazeneca ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Astrazeneca ADR | - | - | - | - | - | - | - |
| GSK plc ADR | -1.290% | 5.909% | 0.866% | 43.827% | 11.483% | 44.720% | 10.296% |
| Bayer AG ADR | 1.750% | -1.724% | -0.870% | 61.702% | 29.545% | -11.628% | -8.800% |
| Novartis AG | -0.960% | 2.219% | 0.407% | 35.803% | 16.957% | 72.775% | 72.775% |
News
Astrazeneca Q2 Earnings Call Highlights
Key Points
- Interested in Astrazeneca Plc? Here are five stocks we like better.
- Solid first-half performance: AstraZeneca reported revenue growth of 6% at constant exchange rates and 11%
Cathie Wood Just Bet Big on This Biotech Stock
Cathie Wood's ARK Genomic Revolution ETF (NYSEMKT: ARKG) focuses on companies in the genomics sector, especially in healthcare. Since the beginning of July, Wood has, through this Ark Invest
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions
Key Points
- Interested in Astrazeneca Plc? Here are five stocks we like better.
- Wainua failed its CARDIO-TTRansform Phase 3 trial by showing no additive benefit for patients already taking